The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineDevelopment and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantHuman parotid secretory protein is a lipopolysaccharide-binding protein: identification of an anti-inflammatory peptide domainRecognition of lipopolysaccharide pattern by TLR4 complexesPathogen recognition and inflammatory signaling in innate immune defensesToll-like receptors: the swiss army knife of immunity and vaccine developmentAdjuvants: Classification, Modus Operandi, and LicensingOuter membrane vesicles as platform vaccine technologyRoles and relevance of mast cells in infection and vaccinationBeyond empiricism: informing vaccine development through innate immunity researchContribution of Toll-like receptor signaling to germinal center antibody responsesSystems biology applied to vaccine and immunotherapy developmentTherapeutic cancer vaccines: past, present, and futureTargeting Toll-like receptors with small molecule agentsMultiple roles of toll-like receptor 4 in colorectal cancerCD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive VaccinesImmune response to vaccine adjuvants during the first year of lifeCombining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protectionCpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumoniaTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesThe Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal PocketSuppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharideThe attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membraneA structure-function approach to optimizing TLR4 ligands for human vaccinesImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsA Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic.Programming the magnitude and persistence of antibody responses with innate immunity.The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.HIV-1 activates macrophages independent of Toll-like receptors.Natural phosphoryl and acyl variants of lipid A from Neisseria meningitidis strain 89I differentially induce tumor necrosis factor-alpha in human monocytesEvasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.Activation of innate immune responses by Haemophilus influenzae lipooligosaccharide
P2860
Q21089976-4A81A196-A9F4-4F14-A864-B3BC711D1531Q21091066-652A609F-E84C-418A-B6EF-7779B80F3E43Q24321459-8D10E307-E483-449A-93F6-F6F7076475BBQ24622138-C8DAE567-9509-48E1-A857-5770CB2AD222Q24643034-97D5DACE-D390-43C7-83AD-4FD5904165F1Q26746644-A29B45A2-6B66-4B8B-A670-721E5D62A507Q26747586-1A0C87CD-7F50-4AED-89D2-B22E17D8646DQ26766539-2DF115FE-6BDB-4073-96BA-DBF9648A067BQ26777264-50DAA141-DF0F-4566-A3F8-C4EC874FC9DBQ26824573-D0DB3DC8-6A51-4508-91C5-7162D41C1A73Q26829061-2BF671D3-4BE3-4299-B5E8-1991969D69E2Q26830374-85639960-3CBC-4223-ABBC-346A4B106D0CQ26863283-64DEC6BF-3EDB-402D-93FE-6866C9BA5909Q26992220-D53CF2C9-703E-4052-99E7-ABC4E56E3C25Q27008380-0ABCEE31-96D3-4A7B-9F8C-C65C184453DEQ27014949-7E5DE875-9A5C-47FC-98BD-25F111D9AF46Q27016633-89C6A140-7D62-4A39-A87B-8CA1854A6D21Q27304818-79F2CE97-F676-4F3E-9CAC-C8C4102E3744Q27318446-A7AEC1A1-1722-4522-B8C1-C8F3A8EA546AQ27322386-4B749C56-BB6E-46C7-A6E2-7DEE2471FE2AQ27675591-E60FAEB8-EFFF-4061-A61D-60FD6679AA58Q28513770-7F2DDE28-8ACF-4609-94AA-FB74F1053836Q28538989-7924AE6C-14B1-4C57-936B-A4BF875EABCFQ28587156-860AB0DD-B40C-477A-B014-45F46AF58AEAQ28818147-FF4E59C1-663D-42FF-918B-7D835776BA43Q28972540-A22FF6E3-1547-4589-8521-73C97C665447Q30145658-6D294387-B3E2-4BF3-AB73-4168DBC3DA2EQ30371303-1E103F74-BC10-408D-AD22-D23F184643DBQ30388683-FFF540AA-ECEA-49E9-9530-3AF56DE95ABEQ30392924-C49312E2-9496-4782-82D0-5F713F36C81EQ30400144-9B22CBC7-ECB7-4741-BE4E-91422BBFC89AQ30406147-D40852D3-04C3-41CB-A320-757F4CE0401CQ30424747-BAEBD01B-CA22-4F8B-BBC2-484A656F01CFQ30425111-CDFBF410-4C09-4F83-8917-8AA8454BD423Q31138173-AFF9F401-1F1D-47D8-BEAC-22647126E176Q33388690-E9E8C233-8105-409E-A2A8-C2D20466A999Q33468766-DD15D720-9837-4D4F-9B36-307D38F19BFCQ33511964-CBBB9560-CE79-48CC-9EC7-55C26C976A70Q33553810-BD5DC3CC-D723-4044-8C41-A2F854BF4E7FQ33601866-A4E6EAFB-210E-4B47-965C-CA0827BCB786
P2860
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
@en
type
label
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
@en
prefLabel
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
@en
P2093
P356
P1433
P1476
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
@en
P2093
Caglar Cekic
Carolyn R Casella
Michael Martin
Thomas C Mitchell
P304
P356
10.1126/SCIENCE.1138963
P407
P577
2007-06-01T00:00:00Z